### **Overview** Jenburkt Pharmaceuticals Ltd is a forward-thinking Indian pharmaceutical company with a strong legacy of innovation, ethical practices, and market responsiveness. With a strategic focus on **pain management, consumer wellness, and rapid adaptation to healthcare trends**, Jenburkt has evolved from a traditional pharma player into a hybrid science-and-wellness enterprise. The company operates exclusively in the **pharmaceutical formulations segment**, with a dual emphasis on prescription-based pharmaceuticals and over-the-counter (OTC) wellness products. --- ### **Core Business Strategy & Organizational Philosophy** - **Three Pillars Framework:** The company’s strategy is built on **Teamwork, Performance, and Agility**, fostering a dynamic, performance-driven culture. - **Agile Transformation:** Jenburkt has transitioned from traditional operating models to agile systems, improving project execution, decision-making speed, and resource allocation. - **Technology Integration:** Leveraging enterprise technologies like **SAP S/4HANA (adopted in 2018–19)** and **LIMS (Laboratory Information Management System)** for seamless operations, quality control, and regulatory compliance. --- ### **Key Business Divisions and Initiatives** #### **1. Pharmaceutical Division** - A leader in **pain management and orthopedic therapeutics**, with flagship brands including: - **Powergesic** (launched 1991): A pioneering muscle relaxant-analgesic combination; now expanded to *Powergesic 2X Gel (2019)*, *Patch (2019)*, and *4X Spray (2024)*. Recognized by over **18,000 prescribers**, accounting for **15% of total product portfolio** with **70% annual growth**. - **ZIX**: A flagship NSAID designed for improved GI safety; prescribed across orthopedics, general medicine, ENT, and dentistry; contributes **10% to portfolio**. - **Nervijen**: **Top-selling brand** in the Vitamin, Mineral & Nutrients category, ranked **No. 6 in India (IQVIA, Feb 2025)**. *Nervijen D3* surpassed first-year revenue targets—its first such milestone. - **New Launches (FY 2024–25):** - *Powergesic 4X Spray* - *Zixflam Forte* - *Zix DT Tablets* (targeting orthopedic care) - *Nervijen CT Tablets* and reformulations like *Jenflam Tablets* #### **2. Jenburkt Wellness Division (Launched 2022)** - Strategic pivot into **consumer wellness**, combining **natural ingredients with scientific research**. - **Zixa Strong**: First OTC and **digital-only brand**, launched April 2022, now expanding into retail (Mumbai, Pune, Bengaluru). - **Product Formats**: Available in **Roll-On, Spray, Gel**, leveraging proprietary **FlashMicelle® Technology**—an oil-in-water micellar system enabling fast absorption, non-greasy application, and rapid, long-lasting relief. - **Key Products:** - *Ortho Pain Massage Oil* - *7-in-1 Multi-Action Balm* - *Zixa Feminine Cream*, *Muscle Recovery Gel*, and more in development. - **Market Expansion**: Expanded presence from 3 to **10 Indian cities** across Gujarat, Maharashtra, and Karnataka. --- ### **Innovation & R&D Excellence** - **R&D Center (Sihor, Gujarat):** Upgraded in 2021, accredited by the Ministry of Science & Technology, and recognized by **DSIR since 2010 (renewed)**. - **Facilities:** Includes formulation lab, wet chemistry lab, stability chambers, and a new **Analytical Process Development Lab** with experienced scientists. - **Focus Areas:** - First-to-market formulations (e.g., *Powergesic*, *Metmin-A*, *Nervijen-P*, *Infartin*) - Fixed-dose combinations for improved patient outcomes - New delivery systems (tablets, gels, sprays, patches) - **Import substitution and cost reduction** - **Innovation Pipeline:** Robust focus on **primary care, pain management, and patient-centric solutions**, with **3–5 new product launches planned** in international markets. --- ### **Digital & Technology Leadership** - **e-Detailing:** Tablet-based system replacing paper, enabling **real-time market tracking and data-driven decisions**. - **Generative AI:** Used across: - Internal creative teams (Adobe Firefly, Midjourney, DALL-E 2, Canva Pro) - Marketing and educational content for HCPs and retailers - Artwork Management software (in implementation) to streamline approvals. - **Digital Sales Platforms:** - Zixa Strong sold via **Amazon, 1mg, and zixa.co**. - **Multi-channel doctor engagement** platform with virtual **CMEs, webinars, and health camps**; over **200 medical education programs** conducted. --- ### **Global Business & Challenges** - **Export Revenue:** ~**₹20 crore (FY 2023–24)** - **Key Challenges:** - **Regulatory & Registration Delays** in key international markets. - **Economic instability in Sri Lanka**: Currency fluctuations, import restrictions, civil unrest affecting demand and distribution. - **Foreign exchange constraints** in African markets (Benin, Kenya, Nigeria). - **Mitigation & Strategy:** - Streamlining regulatory processes for global compliance. - **Local partnerships and supply chain optimization**. - Plans to enter **at least two new countries** and launch **3–5 new products** in existing international markets by 2025. - **Export Resilience:** Continued export fulfillment during pandemic and ongoing crises. --- ### **Corporate Responsibility & Market Access Initiatives** - **Affordability & Access:** - Launched **Favivent™ (Favipiravir)** at **₹39/tablet**—one of India’s most affordable options during the pandemic. - Developed **cost-effective treatments** for regionally prevalent diseases. - **Partnerships for Public Health:** - Collaboration with **Red Cross** for preventive healthcare. - Rural outreach and **telemedicine programs**. - **Sustainability:** - Strict **SOP-driven operations**, CGMP compliance, responsible disposal of expired materials via approved waste partners. --- ### **Brand Building & Strategic Partnerships** - **Official Pain Relief Partner** for 80+ events, including: - **Ladakh Marathon, Mumbai City FC, FC Goa, Indian Football League, and major marathons.** - Supports **10,000+ runners** via recovery centers at 30 marathons. - **Educational Collaborations:** - **Iyengar Yoga e-programs** under "From Illness to Wellness." - **Continuing Physiotherapy Education (CPE)** with **NIMHANS, Bengaluru**. - **Clinical Validation:** **Zixa Strong** officially recommended by **Indian Association of Physiotherapists (IAP)**—12,000+ members. --- ### **Recent Milestones & Recognition** - **Zixa Strong:** - First product to offer single formulation in **three delivery formats**. - Developed in-house using **FlashMicelle® Technology**. - Early consumer data shows **strong repeat purchase behavior**. - **Nervijen D3:** First Jenburkt brand to **exceed first-year revenue target**. - **Favivent™:** Second Indian company to launch Favipiravir; positioned as **accessible treatment during national crisis**.